Eli Lilly acquired Adverum, gaining access to Ixo-vec, a gene therapy for wet age-related macular degeneration. Read why I ...
RBC Capital raised the firm’s price target on Adverum Biotechnologies (ADVM) to $4 from $3 and keeps a Sector Perform rating on the shares. The ...
In advance of CPhI, Cambrex and Wilmington PharmaTech both just announced big investments in US plants that make active ...
Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are utilizing Nvidia technology to either enhance their products or ...
Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer to help with drug discovery and shorten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback